ASHI’s Response to MEDCAC regarding the use of RBC transfusions vs ESA in renal transplant patients.
The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) held a January 19, 2011 hearing on “The Impact of Erythropoiesis Stimulating Agents (ESA) on Renal Transplant Survival.” Dr. Susie Leffell presented comments on ASHI’s behalf. To read her testimony, click here.
Following this hearing there was a February 3, 2011 deadline for comments on the technology assessment portion of “The Impact of Pre-Transplant Red Blood Cell (RBC) Transfusions in Renal Allograft Rejection.” The ASHI leadership submitted comments which will be reviewed and posted by May 3, 2011 at http://www.ahrq.gov/clinic/techix.htm. To read these comments now, click here.
If you have newsworthy information to add to the ASHI Web site, please contact kmiranda@ahint.com for consideration.